In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
43 authors.
Jonathan M MudgeEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, CB10 1SD, UK.ORCID 0000-0003-4789-7495 Jorge Ruiz-OreraCardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, 13125, Germany.ORCID 0000-0002-8317-0034 Ivo Fierro-MontiEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, CB10 1SD, UK.ORCID 0000-0002-5460-2117 Julie L AspdenSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK.ORCID 0000-0002-8537-6204 Elspeth A BrufordHUGO Gene Nomenclature Committee (HGNC), Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge, UK.ORCID 0000-0002-8380-5247 Anne-Ruxandra CarvunisDepartment of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA.ORCID 0000-0002-6474-6413 Sonia ChothaniCentre for Computational Biology and Program in Cardiovascular and Metabolic Disorders, Duke-NUS (National University of Singapore) Medical School, Singapore.ORCID 0000-0002-1010-7069 Jim ClauwaertDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.ORCID 0000-0002-5876-1406 Pouya FaridiCentre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia.ORCID 0000-0002-2712-3356 Adam FrankishEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, CB10 1SD, UK.ORCID 0000-0002-4333-628X Norbert HubnerCardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, 13125, Germany.ORCID 0000-0002-1218-6223 Nicholas T IngoliaDepartment of Molecular and Cell Biology, Center for Computational Biology, University of California, Berkeley, Berkeley, CA, 94720-3202, USA.ORCID 0000-0002-3395-1545 Michele MagraneEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, CB10 1SD, UK.ORCID 0000-0003-3544-996X Maria Jesus MartinEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, CB10 1SD, UK.ORCID 0000-0001-5454-2815 Thomas F MartinezDepartment of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, 92617, USA.ORCID 0000-0002-4011-8164 Gerben MenschaertBiobix, Lab of Bioinformatics and Computational Genomics, Department of Mathematical Modelling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium.ORCID 0000-0002-7575-2085 Sandra OrchardEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, CB10 1SD, UK.ORCID 0000-0002-8878-3972 Xavier RoucouDepartment of Biochemistry and Functional Genomics, Université de Sherbrooke, Sherbrooke, Québec, Canada.ORCID 0000-0001-9370-5584 Aaron WacholderDepartment of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA.ORCID 0000-0001-8739-0029 Wei WuSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore.ORCID 0000-0002-1092-603X Zhi XieState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-5589-4836 Jyoti ChoudharyFunctional Proteomics Group, Institute of Cancer Research, Chester Betty Labs, London, SW3 6JB, UK.ORCID 0000-0003-0881-5477 Michal Bassani-SternbergLudwig Institute for Cancer Research, University of Lausanne, Lausanne, 1005, Switzerland.ORCID 0000-0002-1934-954X Juan Antonio VizcaínoEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, CB10 1SD, UK.ORCID 0000-0002-3905-4335 Nicola TernetteSchool of Life Sciences, Division Cell Signalling and Immunology, University of Dundee, Dundee, DD1 5EH, UK.ORCID 0000-0002-9283-0743 John R PrensnerDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.ORCID 0000-0002-7024-636X Sebastiaan van HeeschPrincess Máxima Center for Pediatric Oncology, Utrecht, 3584 CS, The Netherlands.ORCID 0000-0001-9593-1980 Funding
Systems BiologyU19AG023122 · NIA · TRANSLATIONAL GENOMICS RESEARCH INST · PI NICHOLAS Joseph SCHORK · 2004 to 2026
$102.6MGENCODE Resource ProjectU41HG007234 · NHGRI · SANGER INSTITUTE · PI FLICEK, PAUL · 2013 to 2020
$20.3MProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI CARR, STEVEN A · 2016 to 2025
$17.0MShortening the development cycle time of Trans Proteomic Pipeline tools with high performance computingR01GM087221 · NIGMS · INSTITUTE FOR SYSTEMS BIOLOGY · PI DEUTSCH, ERIC, MORITZ, ROBERT L · 2010 to 2021
$6.0MUnraveling microprotein biology with an evolutionary-immunological frameworkR01AT012826 · NCCIH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Alok Joglekar, Arvind Rasi Subramaniam · 2023 to 2026
$5.9MCenter of Excellence for High Throughput Proteogenomic CharacterizationU24CA270823 · NCI · BROAD INSTITUTE, INC. · PI STEVEN A CARR, MICHAEL A GILLETTE · 2022 to 2026
$5.3MProteogenomic Predictors of Recurrence in Non-small Cell Lung CancerU01CA271402 · NCI · WASHINGTON UNIVERSITY · PI STEVEN A CARR, MICHAEL A GILLETTE · 2022 to 2026
$5.0MThe Nomenclature of Human and Vertebrate GenesU24HG003345 · NHGRI · UNIVERSITY OF CAMBRIDGE · PI Elspeth Bruford · 2018 to 2026
$3.9MIntegrative Omics to enhance therapeutics development for healthy agingUH3AG064706 · NIA · TRANSLATIONAL GENOMICS RESEARCH INST · PI MILLER, RICHARD A, SCHORK, NICHOLAS JOSEPH · 2021 to 2024
$3.3MSmall translated ORFs in the 3'UTR enhance translation in vertebratesR01GM136849 · NIGMS · STOWERS INSTITUTE FOR MEDICAL RESEARCH · PI BAZZINI, ARIEL · 2021 to 2025
$2.0MDeciphering non-canonical translation in high risk medulloblastomaK08CA263552 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI John Prensner · 2022 to 2026
$1.2MThe Roles of a Novel Microprotein in Wound Healing and CancerK01CA249038 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI MARTINEZ, THOMAS FARID · 2021 to 2025
$688kNCCIH NIH HHS R01 AT012826NCI NIH HHS K01 CA249038NCI NIH HHS K08 CA263552NCI NIH HHS P01 CA206978NCI NIH HHS U01 CA271402NCI NIH HHS U24 CA270823NHGRI NIH HHS U24 HG003345NHGRI NIH HHS U41 HG007234NIA NIH HHS U19 AG023122NIA NIH HHS UH3 AG064706NIGMS NIH HHS R01 GM087221NIGMS NIH HHS R01 GM136849NIH HHS S10 OD026936Wellcome Trust
6 · The paper itselfAbstract
A major scientific drive is to characterize the protein-coding genome as it provides the primary basis for the study of human health. But the fundamental question remains: what has been missed in prior genomic analyses? Over the past decade, the translation of non-canonical open reading frames (ncORFs) has been observed across human cell types and disease states, with major implications for proteomics, genomics, and clinical science. However, the impact of ncORFs has been limited by the absence of a large-scale understanding of their contribution to the human proteome. Here, we report the collaborative efforts of stakeholders in proteomics, immunopeptidomics, Ribo-seq ORF discovery, and gene annotation, to produce a consensus landscape of protein-level evidence for ncORFs. We show that at least 25% of a set of 7,264 ncORFs give rise to translated gene products, yielding over 3,000 peptides in a pan-proteome analysis encompassing 3.8 billion mass spectra from 95,520 experiments. With these data, we developed an annotation framework for ncORFs and created public tools for researchers through GENCODE and PeptideAtlas. This work will provide a platform to advance ncORF-derived proteins in biomedical discovery and, beyond humans, diverse animals and plants where ncORFs are similarly observed.
Indexed as
GENCODEHuman Proteome Projectimmunopeptidomicsmass spectrometrymicroproteinsnon-canonical ORFsproteomicsRibo-seqtranslation
Identifiers
PMID39314370
PMCPMC11419116
What OpenQuestion holds
Textmetadata
LicenceCC BY-ND
Read underepoch 390